Phathom Pharmaceuticals 将来の成長
Future 基準チェック /56
Phathom Pharmaceuticalsは、57.4%と28.4%でそれぞれ年率57.4%で利益と収益が成長すると予測される一方、EPSはgrowで57.7%年率。
主要情報
57.4%
収益成長率
57.65%
EPS成長率
| Pharmaceuticals 収益成長 | 14.8% |
| 収益成長率 | 28.4% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Good |
| 最終更新日 | 17 Jun 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • Jun 15
PHAT: Research Momentum And 2026 Profitability Outlook Will Support Bullish Repricing
Analysts have raised their price target on Phathom Pharmaceuticals to $13.62, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E following recent research support. What's in the News Phathom highlighted extensive clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA, at Digestive Disease Week 2026 in Chicago.Seeking Alpha • Jun 09
Phathom: Why I'm Downgrading To "Sell" Ahead Of Competition
Summary Phathom Pharmaceuticals, Inc. is downgraded to Sell due to concerns over growth sustainability, competition, and terminal value assumptions. Q1 sequential revenue growth was flat, raising doubts about Voquezna's adoption beyond early specialists despite management's optimism for future cash generation. Competition from Sebela’s tegoprazan threatens Voquezna’s pricing power and market share, challenging PHAT’s ability to achieve mid-teens FCF margins. PHAT’s valuation relies on aggressive growth and stable terminal value, which is questionable given the 2033 patent cliff and uncertain long-term prospects. Read the full article on Seeking Alpha
ナラティブの更新 • Jun 01
PHAT: Clinical Momentum Will Support Anticipated 2026 Profitability Timeline
Analysts have adjusted their price target on Phathom Pharmaceuticals to $23.70. This reflects updated views on the discount rate, long-term margin potential, and future P/E assumptions following recent research commentary.ナラティブの更新 • May 02
PHAT: Regulatory Exclusivity Outlook Will Support Anticipated 2026 Profitability Timeline
Narrative update on Phathom Pharmaceuticals The updated analyst price target for Phathom Pharmaceuticals has moved to $23.70, with analysts pointing to refreshed models that factor in revised revenue growth and profit margin assumptions, an adjusted future P/E, and recent research highlighting expectations around potential profitability timing, regulatory exclusivity and consumer marketing uncertainty. Analyst Commentary Recent Street research on Phathom Pharmaceuticals highlights a mix of optimism around the path to profitability and caution around long term exclusivity and commercial execution.ナラティブの更新 • Apr 15
PHAT: Regulatory Exclusivity Outlook Supports Path To 2026 Profitability
Phathom Pharmaceuticals' fair value estimate has shifted from $22.90 to $23.70 as analysts factor in higher long term profit margin assumptions, recent price target increases to $25 and $13, and updated views on regulatory exclusivity and potential generic competition after 2032. Analyst Commentary Recent Street research provides a mixed but useful view of how expectations are settling around Phathom Pharmaceuticals' execution and long term earnings power.ナラティブの更新 • Apr 01
PHAT: Profitability In 2026 Will Challenge Post 2032 Generic Overhang
Narrative Update The analyst price target for Phathom Pharmaceuticals is now aligned with a fair value estimate of about $13.62, with analysts pointing to updated models following Q4 results, refined assumptions around revenue growth, profit margins and future P/E, as well as recent target increases to $13 and $25 that reflect views on regulatory exclusivity and the path toward potential profitability in early Q3 2026. Analyst Commentary Recent Street research around Phathom Pharmaceuticals has centered on updated models following Q4 results, with analysts adjusting their targets to reflect revised assumptions on regulatory exclusivity, marketing execution and the timing of potential profitability.ナラティブの更新 • Mar 18
PHAT: Profitability In 2026 Will Test Post 2032 Generic Assumptions
Narrative Update on Phathom Pharmaceuticals Analysts have raised Phathom Pharmaceuticals' price target to a range that now reaches up to $25, up from prior targets as low as $12, citing updated models after the Q4 earnings beat, revised assumptions around regulatory exclusivity and generic entry after 2032, and expectations for the company to work toward profitability in early Q3 2026. Analyst Commentary Analysts reviewing Phathom Pharmaceuticals after its Q4 earnings beat have adjusted their models and price targets, but with differing levels of enthusiasm.ナラティブの更新 • Mar 04
PHAT: Profitability Expected In 2026 Could Reframe Long Term Generic Risk
Narrative Update on Phathom Pharmaceuticals The analyst price target underpinning our fair value view on Phathom Pharmaceuticals has shifted from $12 to $13. This reflects updated models that factor in the recent Q4 earnings beat, revised assumptions on regulatory exclusivity and potential generic entry after 2032, and expectations around the company's path toward potential profitability in early Q3 2026.ナラティブの更新 • Feb 18
PHAT: Follow On Equity Raise Will Support Path To 2026 Profitability
Analysts have kept their $22.90 price target for Phathom Pharmaceuticals broadly unchanged, citing only marginal adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions in their valuation work. What's in the News Phathom Pharmaceuticals completed a follow on equity offering totaling approximately US$130.0 million.ナラティブの更新 • Feb 04
PHAT: Equity Raise And 2026 Profitability Outlook Will Support Further Upside
Analysts have maintained their overall view on Phathom Pharmaceuticals, making only modest adjustments to assumptions such as revenue growth, profit margin, and future P/E. Taken together, these inputs support an unchanged fair value estimate of US$22.90 per share.ナラティブの更新 • Jan 20
PHAT: Equity Raise And 2025 Profitability Outlook Will Support Further Upside
Analysts have modestly adjusted their price assumptions for Phathom Pharmaceuticals, and the implied fair value remains at $22.90. Small changes to revenue growth, profit margin expectations, and future P/E assumptions have effectively offset one another.分析記事 • Jan 08
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27%
Despite an already strong run, Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have been powering on, with a gain...ナラティブの更新 • Jan 06
PHAT: Late-Stage Gastrointestinal Trials And 2025 Guidance Will Drive Upside Momentum
Analysts have maintained their price target for Phathom Pharmaceuticals at US$22.90. This reflects only minor adjustments in key model inputs, including the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any change in their overall view.ナラティブの更新 • Dec 16
PHAT: Late-Stage Gastrointestinal Pipeline Progress Will Drive Upside Momentum
Analysts have slightly trimmed their price target on Phathom Pharmaceuticals from approximately $23.13 to $22.90 per share, reflecting modestly higher long term growth and margin expectations, offset by a lower projected valuation multiple. What's in the News First patient dosed in the Phase 2 pHalcon EoE-201 trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with topline results expected in 2027 (company announcement) Additional analyses from the pivotal Phase 3 pHalcon NERD-301 trial of VOQUEZNA in Non Erosive Reflux Disease published in the American Journal of Gastroenterology, highlighting benefits for nighttime GERD symptoms (company announcement, medical journal) Full year 2025 revenue guidance updated to a range of 170 million dollars to 175 million dollars, indicating expectations for continued commercial ramp (company guidance) Sanjeev Narula appointed Chief Financial and Business Officer, bringing extensive large cap pharma and transaction experience from prior CFO roles at Intra Cellular Therapies, Viatris, and Pfizer divisions (company announcement) Valuation Changes Fair Value Estimate has edged down slightly from approximately $23.13 to $22.90 per share.ナラティブの更新 • Dec 01
PHAT: Clinical Pipeline Advances And Index Inclusion Will Support Upside Momentum
Analysts have maintained their price target for Phathom Pharmaceuticals at $23.13 per share, citing consistent revenue growth expectations and stable profit margin forecasts as the basis for leaving their projections unchanged. What's in the News First patient dosed in Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with primary and secondary results expected in 2027 (Key Developments) Updated full-year 2025 revenue guidance to a range of $170 million to $175 million (Key Developments) New data from Phase 3 pHalcon-NERD-301 trial for VOQUEZNA published, showing improvements in nocturnal symptoms for Non-Erosive Reflux Disease and highlighting safety considerations (Key Developments) Appointment of Sanjeev Narula as Chief Financial and Business Officer, bringing extensive financial and strategic experience from leadership roles at Intra-Cellular Therapies, Viatris, and Pfizer (Key Developments) Added to S&P Pharmaceuticals Select Industry Index (Key Developments) Valuation Changes Consensus Analyst Price Target remains steady at $23.13 per share with no change from previous estimates.ナラティブの更新 • Nov 17
PHAT: Early Clinical Trial Progress Will Drive Shares Higher
Analysts have maintained their fair value price target for Phathom Pharmaceuticals at $23.13 per share. They cite only marginal adjustments to growth estimates and risk assumptions.ナラティブの更新 • Nov 01
PHAT: Rising Profit Margins Will Drive Stronger Shareholder Value Ahead
Analysts have raised their price target for Phathom Pharmaceuticals from $21.38 to $23.13. They cite an improved profit margin outlook, despite more conservative revenue growth projections.ナラティブの更新 • Sep 04
Gastroenterology Focus Will Unlock Enduring Market Potential
Analysts reaffirmed their price target for Phathom Pharmaceuticals at $21.38, citing 10-year market exclusivity for Voquezna, diminished generic risk, and robust launch metrics as drivers of renewed confidence and market opportunity. Analyst Commentary FDA granted 10-year market exclusivity for Voquezna tablets under GAIN, extending exclusivity to May 2032 with a likely pediatric extension through late 2032.分析記事 • Jul 19
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have retraced a considerable 27% in the last month, reversing a...分析記事 • Jun 02
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump
Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shareholders are no doubt pleased to see that the share price has bounced...新しいナラティブ • May 09
Focused VOQUEZNA Marketing And Cost Cuts Will Secure 2032 Exclusivity
Phathom focuses on VOQUEZNA's market potential in GERD treatment to drive substantial revenue while aiming for profitability through strategic cost management.分析記事 • Apr 18
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Unfortunately for some shareholders, the Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) share price has dived 27% in the...Seeking Alpha • Dec 11
Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable
Summary Phathom Pharmaceuticals, Inc.'s vonoprazan received multiple approvals, but the stock price showed erratic behavior, spiking post-Q2 earnings and plummeting post-Q3 earnings. Despite significant prescription growth and revenue increases, Q3 showed slower progress, raising concerns about the drug's market uptake and second-line approval status. High SG&A expenses and limited cash runway pose financial risks, alongside unclear reasons for stagnant sales despite label expansions. I exited my PHAT position in August and have no plans to reinvest due to these uncertainties and financial concerns. Read the full article on Seeking AlphaSeeking Alpha • Sep 03
Following Up On Phathom Pharmaceuticals
Summary Today, we're following up on Phathom Pharmaceuticals to see how the marketing rollout of its flagship product VOQUENZA is proceeding. This drug received FDA clearance late last year and is aiming to displace Proton Pump Inhibitors in its market. Management has succeeded in getting the compound covered in most commercial plans and believes VOQUENZA have at least $3 billion in peak sales potential. However, the company is still seeing a significant quarterly cash burn rate and already has a decent chunk of debt on its balance sheet. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Summary Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation. The delays in launching Voquenza have been frustrating, but now the company is conducting a full launch and may secure a lucrative label expansion with an approval in non-erosive GERD next month. Read the full article on Seeking AlphaSeeking Alpha • Mar 18
Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion
Summary The FDA has set a target action date of July 19, 2024, for expanded approval of Voquenza, which would target the larger Non-Erosive GERD patient population. The global market for GERD therapies is expected to be $3.4 billion by 2032. A soon-to-be-initiated phase 3 study in 2024 is going to explore the use of Voquenza with "As Needed" dosing to treat Non-Erosive GERD patients. Voquenza may also be used to treat patients with another gastrointestinal disorder, such as eosinophilic esophagitis. A phase 2 study using this drug to treat this patient population is expected to be initiated in 2024. Read the full article on Seeking Alpha業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 755 | 241 | 255 | 214 | 9 |
| 12/31/2027 | 540 | 98 | 114 | 100 | 9 |
| 12/31/2026 | 334 | -54 | -45 | -53 | 9 |
| 3/31/2026 | 205 | -157 | -98 | -97 | N/A |
| 12/31/2025 | 175 | -221 | -167 | -167 | N/A |
| 9/30/2025 | 147 | -275 | -225 | -225 | N/A |
| 6/30/2025 | 114 | -330 | -275 | -275 | N/A |
| 3/31/2025 | 82 | -346 | -283 | -283 | N/A |
| 12/31/2024 | 55 | -334 | -267 | -267 | N/A |
| 9/30/2024 | 26 | -339 | -248 | -247 | N/A |
| 6/30/2024 | 10 | -297 | -217 | -215 | N/A |
| 3/31/2024 | 3 | -247 | -168 | -167 | N/A |
| 12/31/2023 | 1 | -202 | -139 | -138 | N/A |
| 9/30/2023 | N/A | -177 | -136 | -135 | N/A |
| 6/30/2023 | N/A | -185 | -139 | -138 | N/A |
| 3/31/2023 | N/A | -195 | -143 | -141 | N/A |
| 12/31/2022 | N/A | -198 | -148 | -147 | N/A |
| 9/30/2022 | N/A | -179 | -147 | -147 | N/A |
| 6/30/2022 | N/A | -164 | -141 | -141 | N/A |
| 3/31/2022 | N/A | -150 | -144 | -143 | N/A |
| 12/31/2021 | N/A | -144 | -149 | -148 | N/A |
| 9/30/2021 | N/A | -162 | -136 | -135 | N/A |
| 6/30/2021 | N/A | -159 | -128 | -127 | N/A |
| 3/31/2021 | N/A | -144 | -109 | -108 | N/A |
| 12/31/2020 | N/A | -129 | -71 | -70 | N/A |
| 9/30/2020 | N/A | -173 | -66 | -65 | N/A |
| 6/30/2020 | N/A | -207 | -52 | -51 | N/A |
| 3/31/2020 | N/A | -274 | -73 | -47 | N/A |
| 12/31/2019 | N/A | -255 | N/A | -37 | N/A |
| 9/30/2019 | N/A | -158 | N/A | -13 | N/A |
| 6/30/2019 | N/A | -90 | N/A | -7 | N/A |
| 3/31/2019 | N/A | -2 | N/A | -2 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: PHATは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。
収益対市場: PHAT今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。
高成長収益: PHAT今後 3 年以内に収益を上げることが予想されます。
収益対市場: PHATの収益 ( 28.4% ) US市場 ( 12.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: PHATの収益 ( 28.4% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: PHATの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/25 04:58 |
| 終値 | 2026/06/25 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Phathom Pharmaceuticals, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15
| アナリスト | 機関 |
|---|---|
| Jenna Davidner | Barclays |
| null null | BMO Capital Markets Equity Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |